
Where artificial persons can profess a faith — Hafiz Hassan
No, it's not a rock band, local or foreign.
It is a United States (US) family-owned company, Hobby Lobby Stores Inc. (Hobby Lobby).
Today it has more than 1000 stores with over 46,000 employees operating in 48 states.
On September 12, 2012, Barbara and David Green, along with their children Mart Green, Steven Green, and Darsee Lett, filed a lawsuit in the US District Court for the Western District of Oklahoma in Oklahoma City, Oklahoma, on behalf of Hobby Lobby.
According to David Green, the founder and CEO of Hobby Lobby, all of the stores that he had founded, including the first store which opened in 1972, incorporated his Christian beliefs into their everyday functions.
In 2012, David and his son Steven, who was the president then, maintained ownership of all of Hobby Lobby stores.
Now, a little background on the case.
On March 23, 2010, then US President Barack Obama signed the Patient Protection and the Affordable Care Act (ACA) into law. The ACA was a legislative overhaul of the US healthcare system that sought to minimise the number of uninsured US citizens.
Many of the ACA's reforms were directed towards healthcare insurers and mandated which services they were required to cover.
The ACA included a provision requiring employer-sponsored health insurance plans to cover certain preventative health services at no cost to the individual.
In the provision, the ACA granted the US Department of Health and Human Services (HHS) in Washington DC authority to determine which preventive services health insurance plans must cover.
On February 15, 2012, the HHS, the US Department of Labor, and the US Department of Treasury finalised regulations that detailed which preventative health services insurers had to cover, which included all contraceptive methods approved by the federal Food and Drug Administration (FDA).
Accordingly, all employer-sponsored health care plans had to cover 14 methods of contraception, free of cost to all female enrollees. However, the HHS regulations included exceptions for certain corporations such as non-profit religious organisations.
The Greens filed their suit against the director of HHS, and challenged the contraceptive mandate of the ACA.
They argued that the contraceptive mandate of the ACA violated the Religious Freedom Restoration Act of 1993 (RFRA) and the Free Exercise Clause of the First Amendment to the US Constitution.
According to the Greens, the contraceptive mandate interfered with their and Hobby Lobby's rights to exercise their religious beliefs by forcing their employer-provided health plans to cover four FDA-approved contraceptive methods that they considered as inducing abortions.
The Greens further argued that under their and Hobby Lobby's religious beliefs, life begins when an egg is fertilised and that emergency contraceptive pills and intrauterine devices both have the potential to prevent a fertilised egg from implanting in the uterus.
The Greens objected to methods inducing abortions by terminating fertilised eggs. They claimed that being mandated to cover those contraceptive methods violated their and Hobby Lobby's rights to exercise their religious freedoms enumerated in the First Amendment to the US Constitution and protected by the RFRA.
In response to the arguments, the HHS contested Hobby Lobby's ability to make claims under the RFRA. The HHS argued that the RFRA, as drafted by US Congress, protected only an individual's right to freedom of religion, not for-profit corporations such as Hobby Lobby. — Pexels pic
In response to the arguments, the HHS contested Hobby Lobby's ability to make claims under the RFRA. The HHS argued that the RFRA, as drafted by US Congress, protected only an individual's right to freedom of religion, not for-profit corporations such as Hobby Lobby.
According to the HHS, Hobby Lobby was a corporation or company composed of individuals with many different beliefs.
The HHS further argued that Hobby Lobby could not claim that the contraceptive mandate burdened the corporation's religious beliefs, as they were a non-religious corporation composed of individuals capable of exercising their personal religious beliefs.
To cut the story short, the case went to the US Supreme Court which granted the federal government's request for review.
The case was consolidated with a similar case from Pennsylvania which challenged the contraceptive mandate of the ACA on similar grounds.
On March 25, 2014, the US Supreme Court began to hear arguments for the case. Three months later in June, the US Supreme Court decided by a slim majority (5:4) in favour of Hobby Lobby.
The majority held that the contraceptive mandate of the ACA placed a burden on the exercise of religion of Hobby Lobby, a corporation but nonetheless a person with the ability to practise religion.
The majority ruled that for-profit corporations are 'persons' by reference to the Dictionary Act 1871 which defines 'person' to include corporations, companies, associations, firms, partnerships, societies, and joint stock companies, as well as individuals.
The majority rejected the federal government's argument that for-profit corporations, which existed primarily to make money, could not exercise religion.
Accordingly, Hobby Lobby had the ability to practise — profess if you like — religion. [See Burwell v. Hobby Lobby Stores, Inc., 573 U.S. 682 (2014)]
The majority decision has been much welcomed and well received as protecting religious freedom in the US, including that of corporations — otherwise called artificial persons.
So yes, artificial persons can profess a faith.
* This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malay Mail
6 hours ago
- Malay Mail
Hospital gave tender to company that failed to deliver cancer treatment machines on time, delaying patients' treatments by months
KUALA LUMPUR, July 21 — A delay in the delivery of critical cancer treatment equipment by a firm has affected patient health care at the Hospital Canselor Tuanku Muhriz (HCTM), revealed the Auditor-General's Report. In an audit report released today, the National Audit Department found that the firm, identified as 0074062-D, failed to provide a linear accelerator (Linac) radiotherapy system as well as a CT-Simulator and Contrast Injector to HCTM on time. The Linac and other supporting equipment were initially scheduled for delivery on September 18, 2024. However, by the time the audit report was concluded on January 17 this year, the Linac machine was yet to be delivered to the said hospital. The report stated that the delay has jeopardised health treatment for at least 20 patients, which was reportedly postponed for up to eight weeks. According to the audit report, the firm failed to supply the equipment on time because the new Linac unit did not meet the technical integration requirements with HCTM's existing system, known as ARIA. 'This technical incompatibility meant that no testing and commissioning work could proceed, further stalling installation and operation,' the report stated. The company then in June last year, asked to postpone the completion of its tender to Feb 12, 2025 due the technical incompatibility, which was approved by HCTM. However, the firm asked for another deferment in December to an unspecified date, which HCTM rejected. Despite the issue, 0074062-D was awarded the contract by the hospital's tender procurement committee. During the tender process, although company 0074062-D met the technical and financial evaluation thresholds, it was not recommended for appointment by the pre-tender committee, technical assessment committee and financial assessment committee. The report stated that the technical assessment committee specifically highlighted that the equipment proposed by the company did not comply with integration requirements for the hospital's existing ARIA system. Despite these concerns, the tender procurement committee proceeded to award the contract to company 0074062-D, overriding the collective recommendations of the evaluation committees. HCTM stated that the tender procurement committee selected company 0074062-D because it fulfilled 90.36 per cent of the technical assessment criteria, submitted the second-lowest bid at RM22 million, and offered the lowest maintenance cost at RM960,000 per year. This was compared to RM1.09 million per year quoted by the lowest bidder in the tender process. However, the National Audit Department found that the explanation unsatisfactory as the report showed the cost saving decision was made despite one company - 0050470-K - submitting a bid for just RM370,000 more than the winning bid, but with the highest score in the technical assessment at 98.05 percent. Apart from the cancer treatment equipment procurement, the Audit Department also raised concerns over two other tenders approved by HCTM — one for catering services and another for lift upgrades. In the catering tender, a RM25.6 million contract was awarded to a company that lacked experience and failed to meet key technical requirements, including having halal certification. Despite not being recommended by the financial assessment committee, the company was chosen due to having sufficient capital. Notably, none of the bidders fully met both technical and financial criteria. Meanwhile, a RM10.8 million contract for lift upgrades was given to company 0726241-U, which had a 'sick project' record — a clear breach of tendering guidelines for major works. Although the hospital claimed that further reviews showed some of the firm's questionable projects were completed on time, the Audit Department maintained that the company should have been disqualified from the start.


Malay Mail
11 hours ago
- Malay Mail
IVD Medical Holding Limited (01931.HK): Officially launched the application for the US stablecoin license and accelerated the landing of the IVDNewCo Exchange ecosystem
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 – IVD Medical Holding Limited( - Forward-looking layout of the historical opportunity of the US "Genius Act", the IVDD stablecoin plan is gathering momentum to set sail and build a new global infrastructure for medical innovative drugs RWA!In the wave of deep integration of global digital finance and medical innovation, IVD Medical Holding Limited( took the lead in building the "NewCo+RWA" Web3 exchange ecosystem (IVDNewCo Exchange) with the construction of medical innovative drugs high-tech assets as the core and the supporting stablecoin "IVDDollar" (IVDD) plan as the core strategy, leading the digital revolution of global medical innovation July 20, 2025, the Board of Directors is pleased to announce that the US subsidiary carrying the Group's aforementioned core strategic mission has landed, and the IVDNewCo Exchange ecosystem has officially landed on the international financial stage. The company released the latest announcement today, officially announcing two milestones: the US wholly-owned subsidiary IVD GROUP INC. has completed registration, and the Group has officially started the process of submitting a stablecoin license application to the US regulator through the subsidiary; at the same time, the Web3 exchange ecosystem with medical innovative drug NewCo assets as the core - IVDNewCo Exchange and its supporting stablecoin IVDD have entered a substantive strategic move not only marks the Group's leading position in the field of compliant digital finance for medical innovative drugs, but also heralds a revolutionary breakthrough in the global medical asset liquidity and value conversion July 18, 2025, local time, US President Trump signed the "Guidance and Establishment of the United States Stablecoin National Innovation Act" (hereinafter referred to as the "Genius Act") at the White House, establishing the legal status of stablecoins as "digital dollars". The implementation of this bill, together with the Stablecoin Ordinance of the Hong Kong Special Administrative Region, which will take effect on August 1, forms a regulatory synergy between the East and the West, and jointly builds the compliance cornerstone of the global stablecoin report of the China Banking Research Institute pointed out that currently 99% of the world's stablecoins are anchored to US dollar assets, and US Treasury bonds have become the core choice of stablecoin reserve assets due to their low risk and high liquidity. In this context, the Group proactively laid out the application for the US stablecoin license, and on July 20 officially announced that the US subsidiary had initiated the process of submitting application materials to regulatory agencies such as the US SEC and CFTC, becoming one of the very few listed companies in the Hong Kong stock market that has completed the "Hong Kong + US" dual hub compliance architecture strategic layout of the Group is deeply in line with the global regulatory trend. By establishing the US subsidiary IVD GROUP INC., we not only meet the strict requirements of the "Genius Act" for 100% reserve asset coverage and independent auditing of stablecoin issuers, but also rely on the sandbox mechanism of the Hong Kong "Stablecoin Ordinance" to build a cross-regional regulatory endorsement system. This dual hub model provides the IVDNewCo Exchange ecosystem with globally rare compliant liquidity support, enabling the Group to establish a first-mover advantage in the "Hong Kong Stock Stablecoin Concept Sector".The core breakthrough of the IVDNewCo Exchange ecosystem lies in the deep integration of Web3 technology and medical innovative drug assets. Relying on the commercial network covering 1,674 tertiary hospitals in China and the ability to acquire high-quality NewCo assets around the world, the Group has created the world's first RWA (real world asset) tokenization platform focusing on medical innovative drugs. The platform achieves the following innovations through blockchain technology:1). Asset tokenization: converting innovative drug assets such as ADC drugs, bi-antibody therapy, and cell gene therapy in the clinical stage into tradable and divisible digital certificates to break through the liquidity bottleneck of traditional medical assets;2). Compliance financial infrastructure: establish an underlying architecture to support the issuance, trading and settlement of IVDD stablecoins, ensuring that each $1 stablecoin corresponds to ultra-short-term U.S. Treasury bonds and other low-risk assets, meeting the U.S. SEC's "1:1 redeemable" requirements;3). Coin-stock linkage mechanism: coordinate with Nasdaq's dual primary listing plan to explore the compound value creation model of "digital assets + traditional equity" to attract two-way inflows of traditional medical capital and crypto-native implementation of this technical architecture has been strongly supported by industry data. Public information shows that the current global innovative drug market has exceeded US$1.2 trillion, and China accounts for 6% of the market with a scale of RMB 450 billion, with an annual compound growth rate of 20.3%. Through the RWA platform, the Group expects to significantly improve the financing efficiency of innovative drug assets, while lowering the entry threshold for investors, allowing small and medium-sized investors around the world to participate in the medical innovation field that was originally limited to institutional Group's strategic advancement has always followed the three-dimensional path of "regulatory compliance-technological innovation-ecological synergy". In the United States, IVD GROUP INC.'s license application strictly follows the requirements of the Genius Act for reserve asset transparency, anti-money laundering (AML) and network security. Its technical system has passed a third-party security audit to ensure that smart contracts are free of loopholes; in Hong Kong, the Group will actively promote participation in the HKMA's stablecoin sandbox program to test reserve asset management and cross-border payment scenarios, laying the foundation for license importantly, the implementation of the IVDNewCo Exchange ecosystem is reshaping the value chain of innovative medical drugs. Under the traditional model, the research and development of innovative drugs requires a cycle of up to 10 years, and 80% of the funds are concentrated in the clinical stage. Through the RWA platform, the Group can monetize clinical-stage assets in advance, provide pharmaceutical companies with low-cost financing channels, and provide investors with dynamic returns linked to the progress of drug development. For example, an ADC drug in Phase II clinical trials can attract global capital participation through tokenization, and its development progress data will be uploaded to the chain in real time to ensure that investors' rights and interests are transparent and Group's strategic initiatives have attracted widespread attention from the capital market and the industry. After the announcement on the 17th, IVD Medical's share price opened sharply higher on the 18th, closing at HK$2.95, up 20.41% throughout the day, with a turnover exceeding HK$9.4886 million and a market value of HK$4.783 billion. Behind the market data is investors' strong confidence in the cross-border integration of "NewCo+RWA+stablecoin".Looking ahead, the Group will continue to deepen the three strategic directions of compliance expansion, technology deepening and ecological integration. Against the backdrop of the global low interest rate environment and the surge in demand for medical innovation, it will use Web3 technology as a bridge to connect traditional medical capital and digital financial innovation. We firmly believe that through compliance layout and technological innovation, the IVDNewCo Exchange ecosystem will become a value amplifier for global innovative medical drug assets, creating a win-win situation for patients, pharmaceutical companies and #IVDMedicalHoldingLimited The issuer is solely responsible for the content of this announcement.


Malay Mail
a day ago
- Malay Mail
Health authorities investigate mysterious deaths of timber workers in Ulu Baram
MIRI, July 20 — The Miri Division Health Office has confirmed receiving preliminary reports of melioidosis cases and multiple fatalities involving workers near Sungai Kalai in Ulu Baram. According to health officer Dr P. Raviwharmman Packierisamy, a team comprising a medical officer and health inspectors has been deployed to the affected camp, which is located approximately nine to ten hours' drive from Miri via off-road timber tracks. 'A team from the Miri Division Health Office has been dispatched to the site to conduct investigations, screen other individuals with symptoms, make early referrals to the nearest healthcare facilities, and carry out health education, sanitation, and disease control measures,' he told The Borneo Post. The action follows reports of recent deaths involving several workers in the Ulu Baram area over the past week. Dr Raviwharmman noted that the health office has been working closely with the camp's management and that cooperation from the latter has been constructive. He emphasised that the situation remains isolated and is currently under control. It is understood that four men have died in recent weeks, with the most recent fatality recorded yesterday. The individual reportedly passed away while receiving treatment at Miri Hospital. The series of deaths has reportedly raised concern and unease among nearby village communities, prompting heightened monitoring by the authorities. — The Borneo Post